Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
INTS
$3.22
+0.31%
INTS
· Intensity Therapeutics, Inc.
$3.22
+0.01 (+0.31%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$12.41M
Shares
3.26M
Volume · Oct 2
964
Avg daily vol (3M)
30.04K
All webcasts
Earnings call · FY2023 Q2
Intensity Therapeutics, Inc. (INTS) Q2 2023 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Diluted EPS
-$35.75
Net income
-$3.70M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 14, 2023 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 14, 2023 · complete as-filed document